Gilead Sciences, Inc. (GILD) Monday announced that the Phase 3 EVOKE-01 study failed to meet its primary endpoint of overall survival in previously treated metastatic non-small cell lung cancer or NSCLC.
In the pre-market session, GILD is at $80.24, down 7.90 percent from the previouse close of $86.40 on a volume of 6,400,664.
EVOKE-01, a global, multi-center, open-label Phase 3 study, evaluated Trodelvy vs. docetaxel in patients with metastatic or advanced NSCLC that had progressed on or after platinum-based chemotherapy and checkpoint inhibitor therapy.
Gilead plans to discuss results with regulators and to present the data at an upcoming medical meeting.
The company said a numerical improvement in overall survival favoring SG was observed in the study, including in patients with both squamous and non-squamous histology.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.